BPC-157 + TB-500

Scientific identity — BPC-157 component: BPC-157 is a synthetic 15-amino-acid pentadecapeptide (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) derived from a partial sequence of body protection compound (BPC), a protein isolated from human gastric juice. It is a linear peptide without disulfide bridges. Research has examined it in relation to VEGF upregulation, nitric oxide/eNOS signaling, growth factor receptor pathways, and gastrointestinal and musculoskeletal tissue models.

Scientific identity — TB-500 component: TB-500 is a synthetic peptide fragment corresponding to residues 17–23 of Thymosin Beta-4 (Tβ4) — specifically the actin-binding domain sequence Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln (Ac-LKKTETQ). Thymosin Beta-4 is a 43-amino-acid water-soluble protein found in platelets, wound fluid, and various tissues throughout the mammalian body. The 17–23 region contains the LKKTET motif — the core actin-sequestering domain of Tβ4 — studied in relation to G-actin binding, cytoskeletal dynamics, and cellular motility in experimental systems.

Distinction between TB-500 and full-length Tβ4: TB-500 is a short synthetic fragment of Tβ4, not the full-length 43-amino-acid protein. The two have different molecular weights, sequences, and research profiles. Findings from full-length Tβ4 research should not be attributed to TB-500 without direct experimental evidence using the fragment.

Blend compositions.

Variant A: 5mg BPC-157 + 5mg TB-500 (10mg total peptide content)

Variant B: 10mg BPC-157 + 10mg TB-500 (20mg total peptide content)

Primary research contexts.

BPC-157: VEGF-mediated angiogenesis; nitric oxide/eNOS signaling; tendon, ligament, and gastrointestinal tissue models

TB-500: Actin sequestration; G-actin binding; cellular motility; anti-fibrotic tissue biology

Research areas: Angiogenesis research, actin cytoskeleton biology, tendon and ligament tissue models, cellular motility research, gastrointestinal tissue biology, musculoskeletal tissue research, anti-fibrotic signaling models.

Purity: Each peptide component characterised to greater than 99% individual purity, confirmed by HPLC and LC-MS analysis at the batch level.

Analytical documentation: A batch-specific Certificate of Analysis is available on the Longevia Research website, covering identity, purity, and lot traceability for both peptide components.

Research-use classification: For laboratory research use only. Not for human or veterinary use, clinical diagnostics, or any in-vivo application in humans.

BPC-157: Angiogenesis and VEGF Signaling Research

BPC-157's primary mechanistic research focus in the published preclinical literature involves angiogenesis — the formation of new blood vessels from pre-existing vasculature. Animal studies have examined BPC-157 in ischemic tissue models — including experimental tendon transection and crush injury models in rodents — measuring VEGF expression, endothelial cell proliferation, and capillary density as angiogenic endpoints. Research has proposed that BPC-157-associated VEGF upregulation in these models creates vascular supply to avascular or poorly vascularised tissues including tendons and ligaments. These findings are model-specific observations in defined rodent experimental systems.

BPC-157 has also been examined in relation to nitric oxide signaling — specifically eNOS activation — and growth factor receptor pathways including VEGFR2 in cell-based systems. The precise molecular mechanism connecting BPC-157 to VEGF upregulation and eNOS activation is an active area of research; no single established direct receptor target has been confirmed across all experimental contexts.

TB-500: Actin Sequestration and Cellular Motility Research

TB-500's primary research mechanism involves the LKKTET actin-binding motif — the core sequence responsible for Thymosin Beta-4's well-characterised G-actin sequestration activity. G-actin sequestration by the LKKTET motif reduces the pool of actin available for filament polymerisation, altering cytoskeletal dynamics and increasing cellular motility in experimental systems. Research has examined TB-500 in cell-based systems measuring actin dynamics, lamellipodia formation, and fibroblast, endothelial cell, and keratinocyte migration parameters.

Animal studies using Thymosin Beta-4 and the TB-500 fragment have investigated anti-fibrotic properties — specifically suppression of myofibroblast differentiation and collagen scar formation — in cardiac and other tissue injury models. These findings concern the fragment's actin-mediated effects on cellular behaviour in defined experimental systems and should not be extrapolated to human tissue outcomes.

Complementary Research Mechanisms

BPC-157 and TB-500 have been examined together in preclinical research because their proposed mechanisms operate through distinct, non-competing cellular pathways — BPC-157 extracellularly via VEGF-mediated vascular supply and growth factor signaling, and TB-500 intracellularly via actin cytoskeletal dynamics and cellular motility. Research has investigated whether simultaneous exposure to both peptides in experimental tissue models produces additive effects on measured endpoints including fibroblast activity, endothelial cell behaviour, and tissue histology parameters. These combined-peptide findings are preclinical observations in defined animal and cell systems. Combined-peptide interactions in biological systems are a separate research question from each peptide's independent literature and require direct experimental verification.

Research Status

Both BPC-157 and TB-500 are preclinical research compounds. No completed human clinical trial data is available in peer-reviewed literature for either peptide, and neither holds regulatory approval for any therapeutic indication in any jurisdiction. All controlled findings in the published literature derive from cell-based and animal experimental systems.

Reliable research begins with accurately characterised material. For a combination vial containing two distinct synthetic peptides — one proline-rich linear pentadecapeptide and one short acetylated heptapeptide fragment — that means confirming the sequence integrity and purity of each component individually at the batch level. The proline-rich N-terminal region of BPC-157 presents specific synthesis challenges that make LC-MS identity confirmation particularly important; similarly, TB-500's short sequence and N-terminal acetylation require verification to confirm the fragment is complete and correctly modified.

Purity assessment: Each peptide component is characterised to greater than 99% individual purity by high-performance liquid chromatography (HPLC). Chromatographic purity data for both components is reported on the batch Certificate of Analysis.

Identity confirmation: The identity of both BPC-157 and TB-500 is confirmed by mass spectrometry (LC-MS), providing molecular-weight verification consistent with the complete sequence of each component. HPLC and LC-MS data together confirm that both materials correspond to their labelled compounds at the labelled purities.

Batch traceability and Certificate of Analysis: Every vial of the BPC-157/TB-500 Blend — both the 5mg/5mg and 10mg/10mg variants — is traceable to a specific production lot. A batch-specific Certificate of Analysis is accessible directly on the Longevia Research website, covering purity, identity, and lot information for both components. Researchers are encouraged to review the current batch documentation before use.

Handling: This material should be handled by qualified personnel using appropriate laboratory technique and personal protective equipment, consistent with institutional protocols for research-grade synthetic peptides.

Longevia Research supplies the BPC-157/TB-500 Blend — in 5mg/5mg and 10mg/10mg variants — for laboratory and in-vitro research use only. The product is intended for use by qualified researchers and trained laboratory personnel in appropriate controlled research environments.

Both BPC-157 and TB-500 are synthetic research peptides supplied strictly as research tools. This combination vial is not a drug, not a dietary supplement, not a food or food ingredient, and not a cosmetic. No regulatory authority has approved either BPC-157 or TB-500 for any human or veterinary therapeutic use, and Longevia does not supply this product for administration to humans or animals, for clinical diagnostics, or for any therapeutic purpose.

Longevia provides no dosing instructions, administration guidance, treatment protocols, or reconstitution recommendations for this combination product. The scientific literature summarised on this product page describes experimental observations exclusively in defined cell-based and animal model systems. Those findings are not medical claims and should not be interpreted as evidence of human efficacy, human safety, or fitness for any clinical application.

The purchaser assumes full responsibility for lawful acquisition, handling, storage, use, and disposal of this material, and for compliance with all applicable local, state, federal, and institutional regulations. By purchasing this product, the buyer confirms that it will be used solely for legitimate laboratory research purposes by qualified personnel, and that its acquisition and intended use comply with applicable laws in the buyer's jurisdiction.